top of page
Background (2220 x 650 px).png

Join uBriGene’s
Educational Live Webinars on ATMPs

Live Webinars on the Development and cGMP manufacturing of Advanced Therapy Medicinal Products 

uBriGene is your bridge from ATMPs concept to commercialization. We have 4 Centers of Manufacturing Excellence: cell therapy (CAR-T, CAR-NK, iPSC, MSC), plasmids, viral vectors (AAV, lentiviral vectors, retroviral vectors, adenovirus), and mRNA.

We are pleased to sponsor an educational series on the basics of advanced therapy development and manufacturing.

RNA Manufacturing 101

September 2024 Webinar: RNA Manufacturing 101: IVT Workflows for GMP Manufacturing

RNA-based therapy has been an expanding area of clinical research since the COVID-19 outbreak. Beyond vaccines, RNA therapies are now being developed to treat a growing number of disease indications. The rapid advancement of RNA drugs has taken various forms, including siRNA, sgRNA, mRNA, circRNA, and saRNA.


In this webinar, we will explore the fundamentals of RNA drug development and the critical role of in vitro transcription (IVT) in manufacturing workflows.


What You’ll Learn:

  • Basics of RNA drug development and the current landscape.

  • Overview of GMP manufacturing workflows for RNA therapies.

  • Key aspects of in-process and release testing panels.


This session is perfect for professionals looking to deepen their understanding of RNA manufacturing processes and ensure their workflows are GMP-compliant.


Presenter: Kenneth Warrington, Ph.D., Executive Director, Strategic Business Development, Head of Technical Services.

Kenneth Warrington, Ph.D.

Lentiviral Vector Basics

June 2024 Webinar: Lentiviral vector basics for cell therapy applications

The goal of this webinar is to:  


- Understand the basics of Lentiviral Vector (LV): definition and characteristics of LV, and their mechanism of action in gene-modified cell therapies. 


- Explore current manufacturing approaches for LV: an overview of existing platforms and technologies, as well as key considerations in LV production scalability and efficiency. 


- Discuss strategies to accelerate LV deployment in cell therapy: the importance of early identification of critical raw materials, and criteria for selecting a proven manufacturing platform, also impact on time-to-market and therapeutic accessibility


Presenter: Kenneth Warrington, Ph.D., Executive Director, Strategic Business Development, Head of Technical Services.

Kenneth Warrington, Ph.D.

CAR-T Therapy 101

April 2024 Webinar: “CAR-T 101”, the basics of CAR-T therapies, from concepts to GMP manufacturing.

In the first presentation, you will gain a comprehensive understanding of  CAR-T therapies, including: 


- The general requirements for the development of CAR-T therapies


- General approaches to gene modification of T-cells 


- High level discussion of GMP manufacturing workflows 


- Regulatory considerations for clinical application of these therapies


Presenter: Kenneth Warrington, Ph.D., Executive Director, Strategic Business Development, Head of Technical Services.

Kenneth Warrington, Ph.D.
bottom of page